Compare TGTX & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | AG |
|---|---|---|
| Founded | 1993 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.4B |
| IPO Year | 2008 | 2004 |
| Metric | TGTX | AG |
|---|---|---|
| Price | $55.16 | $17.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $49.80 | $21.92 |
| AVG Volume (30 Days) | 2.8M | ★ 11.6M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.12% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.08 | $24.41 |
| Revenue Next Year | $26.69 | $10.68 |
| P/E Ratio | $457.67 | ★ $143.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $7.74 |
| 52 Week High | $57.38 | $32.00 |
| Indicator | TGTX | AG |
|---|---|---|
| Relative Strength Index (RSI) | 77.96 | 45.78 |
| Support Level | $28.57 | $15.61 |
| Resistance Level | $57.38 | $20.00 |
| Average True Range (ATR) | 2.39 | 0.94 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 81.53 | 41.71 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.